[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

Rhea-AI Filing Summary

Ross Moat, Chief Corporate & Commercial Officer of Kiniksa Pharmaceuticals International (KNSA), reported multiple equity transactions on September 1-2, 2025. The filing shows grant and acquisition of restricted share units (RSUs) and a stock option, and reported dispositions of Class A ordinary shares at prices of $33.49 and $34.28. The derivative section shows an option for 39,364 Class A shares and RSUs representing 9,828 Class A shares, each with specified multi-year vesting schedules. Following the reported transactions, the Form 4 lists beneficial ownership figures for Class A ordinary shares in the range shown, with the last reported post-transaction direct ownership of 12,938 Class A ordinary shares. The filing includes detailed vesting terms: option vesting begins September 1, 2025, and RSUs vest over four-year schedules with 25% annual vesting.

Positive

• Detailed vesting schedules disclosed for RSUs and options, providing transparency on when awards become exercisable or convertible.
• Large option grant (39,364 shares) aligns executive incentives with long-term shareholder value given multi-year vesting.

Negative

• Reported share dispositions at $33.49 and $34.28 reduced the reporting person’s immediate beneficial holdings.
• Grants may cause future dilution if options are exercised and RSUs convert to Class A shares over time.

Insights

Financial Analyst

TL;DR: Insider received compensation in equity and sold some shares; options and RSUs vest over multiple years, modest near-term shareholder impact.

The filing documents routine equity compensation and limited share dispositions by a senior officer. The grant of a 39,364-share option and nearly 9,828 RSUs increases potential future dilution but these awards vest over multi-year schedules, delaying full economic impact. Reported sales at $33.49 and $34.28 realize proceeds and reduce immediate insider shareholdings to the reported post-transaction direct ownership level of 12,938 Class A shares. For investors, this represents standard executive compensation activity rather than a corporate event affecting operations or guidance.

Corporate Governance Expert

TL;DR: Transactions reflect standard equity-based pay and scheduled vesting; disclosure is complete with vesting timelines and exercised/sold amounts.

The Form 4 provides clear disclosure of awards and dispositions by the reporting person, including specific vesting commencement dates and schedules for RSUs and options. The combination of immediate share dispositions and long-term vesting aligns with common governance practices to balance liquidity and retention. No departures from standard disclosure practices or indications of unusual timing are evident within the filing itself.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moat Ross

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF CORP. & COMM. OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	09/01/2025		M		1,741	A	(1)	11,156	D
Class A Ordinary Share	09/01/2025		M		1,611	A	(1)	12,767	D
Class A Ordinary Share	09/01/2025		M		2,477	A	(1)	15,244	D
Class A Ordinary Share	09/01/2025		F		2,819	D	$33.49	12,425	D
Class A Ordinary Share	09/02/2025		M		994	A	(1)	13,419	D
Class A Ordinary Share	09/02/2025		F		481	D	$34.28	12,938	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Unit	(1)	09/01/2025		A		9,828		(2)	(2)	Class A Ordinary Share	9,828	$0	9,828	D
Share Option	$33.49	09/01/2025		A		39,364		(3)	08/31/2035	Class A Ordinary Share	39,364	$0	39,364	D
Restricted Share Unit	(1)	09/01/2025		M			1,741	(4)	(4)	Class A Ordinary Share	1,741	$0	5,221	D
Restricted Share Unit	(1)	09/01/2025		M			1,611	(5)	(5)	Class A Ordinary Share	1,611	$0	3,222	D
Restricted Share Unit	(1)	09/01/2025		M			2,477	(6)	(6)	Class A Ordinary Share	2,477	$0	2,477	D
Restricted Share Unit	(1)	09/02/2025		M			994	(7)	(7)	Class A Ordinary Share	994	$0	0	D

Explanation of Responses:

1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

2. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025.

3. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025.

4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.

5. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.

6. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

7. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021.

	/s/ Aaron Young, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did KNSA officer Ross Moat report on Form 4?

The Form 4 reports acquisitions of RSUs and a stock option and dispositions of Class A ordinary shares on September 1-2, 2025.

How many stock options and RSUs were reported in the filing?

The filing shows a 39,364-share option grant and RSUs representing 9,828 Class A ordinary shares (plus other outstanding RSU amounts listed).

At what prices were shares sold according to the Form 4?

Dispositions were reported at prices of $33.49 and $34.28 per Class A ordinary share.

What is Ross Moat’s reported post-transaction beneficial ownership?

The Form 4 shows a post-transaction direct ownership figure of 12,938 Class A ordinary shares following the reported transactions.

When do the awarded RSUs and options vest?

Vesting schedules specify four-year annual 25% vesting for RSUs with various grant dates and an option that vests 25% after one year then monthly over 36 months, with a vesting commencement date of September 1, 2025 for the option.